Global state: any change in global state – unspecified problem necessitating change in dose or type of antipsychotics – medium term · patients with schizophrenia
It is very uncertain whether aspirin plus antipsychotics changes global state: any change in global state – unspecified problem… compared with placebo plus antipsychotics (very low certainty).
1 finding from 1 review
Duration of delirium Days · delirious patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severity of delirium · delirious patients
1 finding from 1 review
Delirium resolution DRS, DRS‐R981 · delirious patients
It is very uncertain whether antipsychotics changes delirium resolution DRS, DRS‐R981 compared with nonantipsychotics or placebo (very low certainty).
1 finding from 1 review
All‐cause mortality · delirious patients
Antipsychotics showed no clear difference in mortality compared with nonantipsychotics or placebo (moderate certainty).
1 finding from 1 review
Length of hospital stay · delirious patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · delirious patients
It is very uncertain whether antipsychotics changes adverse Effects ‐ EPS Extrapyramidal Symptom Rating Scale, or not… compared with nonantipsychotics or placebo (very low certainty).
1 finding from 1 review
BPD symptom severity Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder
1 finding from 1 review
Self‐harm Measured by: clinicians Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether antipsychotics changes self‐harm Timing of outcome assessment: end of treatment (8 to 24… compared with placebo (very low certainty).
1 finding from 1 review
Suicide‐related outcomes Timing of outcome assessment: end of treatment (6 to 12 weeks treatment duration) · patients with borderline personality disorder
1 finding from 1 review
Psychosocial functioning Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder
1 finding from 1 review
Interpersonal problems Timing of outcome assessment: end of treatment (32 days to 24 weeks) · patients with borderline personality disorder
1 finding from 1 review
Attrition Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether antipsychotics changes attrition Timing of outcome assessment: end of treatment (5 weeks to… compared with placebo (very low certainty).
1 finding from 1 review
Non‐serious adverse events Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether antipsychotics changes non‐serious adverse events Timing of outcome assessment: end of… compared with placebo (very low certainty).
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with trichotillomania
Antipsychotics may leads to higher treatment responseaClinical Global Impressions ‐ Improvement Scale… compared with placebo (low certainty).
1 finding from 1 review
Reduction of TTM symptom severityMassachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS) · adults with trichotillomania
1 finding from 1 review
Withdrawals due to adverse events · adults with trichotillomania
1 finding from 1 review
Repetition of SH at post‐intervention · self‐harm in adults
Antipsychotics may leads to lower repetition of SH by post‐intervention№ of participants: 30(1 RCT) compared with placebo (low certainty).
1 finding from 1 review
OR 0.09 [0.02, 0.5]
Studies not reported
Low
Repetition of SH at post‐intervention · self‐harm in adults
Antipsychotics showed no clear difference in repetition of SH by post‐intervention№ of participants: 53(1 RCT) compared with another comparator drug or dose (low certainty).
1 finding from 1 review
OR 1.51 [0.5, 4.58]
Studies not reported
Low
Repetition of SH at 6 months' · adults who engage in SH
It is very uncertain whether antipsychotics changes repetition of SH at six months (flupenthixol vs. placebo) compared with placebo or another comparator drug/dose (very low certainty).
1 finding from 1 review